MicroRNA characterization in equine induced pluripotent stem cells

Lucia Natalia Moro¹, Guadalupe Amin¹, Veronica Furmento¹, Ariel Waisman¹, Ximena Garate¹, Gabriel Neiman¹, Alejandro La Greca¹, Natalia Lucia Santín Velazquez¹, Carlos Luzzani¹, Gustavo E. Sevlever¹, Gabriel Vichera², Santiago Gabriel Miriuka¹*

¹ LIAN-CONICET, Fundación FLENI, Buenos Aires, Argentina, ² Kheiron Biotech, Pilar, Buenos Aires, Argentina

Abstract

Cell reprogramming has been well described in mouse and human cells. The expression of specific microRNAs has demonstrated to be essential for pluripotent maintenance and cell differentiation, but not much information is available in domestic species. We aim to generate horse iPSCs, characterize them and evaluate the expression of different microRNAs (miR-302a,b,c,d, miR-205, miR-145, miR-9, miR-96, miR-125b and miR-296). Two equine iPSC lines (L2 and L3) were characterized after the reprogramming of equine fibroblasts with the four human Yamanaka's factors (OCT-4/SOX-2/c-MYC/KLF4). The pluripotency of both lines was assessed by phosphatase alkaline activity, expression of OCT-4, NANO and REX1 by RT-PCR, and by immunofluorescence of OCT-4, SOX-2 and c-MYC. In vitro differentiation to embryo bodies (EBs) showed the capacity of the iPSCs to differentiate into ectodermal, endodermal and mesodermal phenotypes. MicroRNA analyses resulted in higher expression of the miR-302 family, miR-9 and miR-96 in L2 and L3 vs. fibroblasts (p<0.05), as previously shown in human pluripotent cells. Moreover, downregulation of miR-145 and miR-205 was observed. After differentiation to EBs, higher expression of miR-96 was observed in the EBs respect to the iPSCs, and also the expression of miR-205 was induced but only in the EB-L2. In addition, in silico alignments of the equine microRNAs with mRNA targets suggested the ability of miR-302 family to regulate cell cycle and epithelial mesenchymal transition genes, miR-9 and miR-96 to regulate neural determinant genes and miR-145 to regulate pluripotent genes, similarly as in humans. In conclusion, we could obtain equine iPSCs, characterize them and determine for the first time the expression level of microRNAs in equine pluripotent cells.

Introduction

Generating domestic animal embryonic stem cells has been proved to be difficult and has sparked the interest on induced pluripotent stem cells (iPSCs) in these species [1]. In the horse, this technology has emerged as a promising therapeutic alternative for musculoskeletal injuries in athletic animals. In contrast to mesenchymal stem cells that have been used for
tissue regeneration in the last decade [2–4], iPSCs have the advantages of indefinite proliferation and higher differentiation potential [5]. In fact, equine iPSCs myogenic differentiation capability has already been probed for skeletal muscle regeneration [6].

Several groups have reported the generation of iPSCs in the horse by reprogramming adult fibroblasts, fetal fibroblasts, keratinocytes and adipose-derived stem cells [6–9]. With these reports, it is clear that equine iPSCs can be generated from different sources, with the capacity to differentiate into all three germinal layers both in vitro and in vivo. However, there is scarce information about the processes involved in equine cell reprogramming, stem maintenance and cell differentiation, in contrast to other species like human or mouse. It is well known from these two models that the biogenesis of microRNAs is a critical process for cell reprogramming and differentiation [10–14]. microRNAs are short non-coding RNA molecules that mainly regulate mRNAs by post-transcriptional targeting of the 3'UTR tail [15], either blocking their translation or inducing its degradation [16]. However, interaction of microRNAs with other regions, such as the 5' UTR, coding sequences, and gene promoters, have also been reported [17, 18]. It has been demonstrated that a single microRNA can regulate the expression of hundreds of mRNA targets [19], a property given by a short sequence (called ‘seed’) in position 2-8 from the 5’ end. The seed is essential for the binding of the microRNA to the mRNA and complementary to microRNA-recognition sequences present in the 3’UTR tail of the mRNAs [20]. microRNA regulation capacity is so marked that human and murine iPSCs have been efficiently generated by only inducing the expression of the miR-302/367 cluster, without the need of the OCT-4/SOX-2/KLF4/c-MYC reprogramming factors [21, 22]. The mir-302/367 cluster is a central player of pluripotent stem cell maintenance, self-renewal and differentiation [23, 24]. On the other hand, other microRNAs are involved in lineage determination by repressing the expression of OCT-4, SOX-2 and KLF4, such as miR-145 that is involved in mesoderm and ectoderm differentiation [25, 26]. miR-9 and miR-96 were shown to be involved in neurogenesis [27–29], and miR-125b was shown as an important regulator of stem cells differentiation to mesoderm and cardiac muscle [30], among others. All together, microRNAs has been extensively shown to regulate critical processes in embryo development.

Until now, there is no information about equine microRNA expression neither in iPSCs nor in embryos. The possibility of elucidating the microRNA expression and regulation in equine iPSCs could enable us to manipulate them and induce cell reprogramming and differentiation more efficiently in this species as was previously demonstrated in the mouse [31]. The objective of this work is to generate horse iPSCs lines, to characterize them and to evaluate the expression of specific microRNAs critical for embryo development. We are interested in exploring whether these processes are similar to those reported for the human and the mouse that have been extensively studied.

**Materials and methods**

**Reagents**

Except otherwise indicated, all chemicals were obtained from Thermo Fisher Scientific (Waltham, Massachusetts, USA). Media were prepared weekly and filtered through 0.22 μm membranes.

**Animal care and use of research animals**

The present study was carried out following the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching. The protocols involving animal manipulations were approved by the Institutional Committee for the Care and Use of Experimental...
Animals of the San Martin National University, Buenos Aires, Argentina (CICUAE-UNSAM, Permit Number: 001/16).

**Cell culture**

Equine fibroblasts were obtained from the skin sample of a spontaneously aborted 5-month-old foetus of Polo Argentino breed. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, catalog number 12100-46) supplemented with 10% foetal bovine serum (FBS) and 1% penicillin/streptomycin (Pen/Strep, 15140-122) in a 5% CO\(_2\), humidified atmosphere at 37°C. After reprogramming, the iPSCs were cultured over inactivated mouse embryonic fibroblast (iMEFs) in eqHES medium [DMEM/F12 (11320033) with 20% Knock-out serum replacement (A3181502), 10 ng/ml basic fibroblast growth (PHG0263), 1% Pen/Strep and 10 ng/ml Human Leukemia Inhibitory Factor (hLIF) (PHC9484)].

**Lentiviral vector production**

Cell reprogramming was performed by using the EF1a-hSTEMCCA-loxP (STEMCCA) lentiviral cassette containing the human genes **OCT-4/SOX-2/KLF4/c-MYC**, generously provided by Dr. Gustavo Mostoslavsky [32]. The lentiviral vectors were produced as previously described by our lab [33], with minor modifications. Briefly, HEK-293 T cells were transfected with the FuGENE6 containing the STEMCCA and helper plasmids. The supernatants were collected 72 h post-transfection and ultracentrifuged at 76221 g for 1 h 30 minutes in a SW 40 Ti rotor. The concentrated virus was then resuspended in cold PBS, aliquoted and stored at -80°C until used. Viral titer was determined as previously described by our lab [33].

**Equine iPSCs lines generation by STEMCCA virus**

Equine fibroblasts were thawed and cultured as described above for 7 days before infection. On day -1, 1x10\(^5\) cells were plated on 1 well of a 6 well plate previously coated with 0.1% bovine gelatin. The day of infection (Day 0), cells were incubated for 16 h with the STEMCCA lentivirus at a titer of MOI 1 and 10 μg/ml of polybrene (TR-1003, Sigma Aldrich, San Luis, Missouri, USA). Spinfection was performed by centrifuging the plate at 700 g for 55 minutes before incubation. On day 1, the virus was removed and the cells were cultured in DMEM medium for 5 days when the first colonies appeared. On day 6, the infected cells were trypsinized and plated in different dilutions (1:4, 1:16, 1:40) over iMEFs in eqHES medium to allow colonies to grow. Twelve colonies were selected according to morphology and mechanically picked from the plate after 2 weeks and cultured in the same conditions. Clonal expansion was performed for 2 colonies, which were amplified and characterized (L2 and L3 lines). For each passage, colonies were detached with collagenase (17100017) centrifuged and plated on iMEF in eqHES medium. Both L2 and L3 lines were maintained in culture over 25 passages.

**Alkaline phosphatase staining**

Alkaline phosphatase activity was determined in both iPSC lines and fibroblasts using a commercial kit (86R-1KT, Sigma-Aldrich) following the manufacturer’s instructions.

**In vitro differentiation to embryo bodies**

Differentiation of L2 and L3 to embryo bodies (EBs) was performed as previously described by Breton et al. (2013) [9] with minor modifications. Briefly, L2 and L3 colonies were treated with collagenase to allow detachment, passaged in a non-adherent culture dish and cultured in suspension for 7 days in DMEM with 10% FBS. Under these conditions, EBs were formed and
after 7 days they were passaged to gelatin-coated adherent-dishes with the same culture conditions for 2 more weeks. After this time, samples were prepared using TRIzol reagent (15596026) for total RNA extraction or the cells were fixed for immunostaining, as explained below.

**RNA extraction, cDNA synthesis and real time PCR**

RNA extraction from the different cell lines was performed with TRIzol reagent. For cDNA synthesis, 500-1000 ng of the total RNA was retro-transcribed with MMLV reverse transcriptase (Promega, WI, USA), according to manufacturer’s instructions. For microRNA reverse transcription, cDNA was generated as previously described using SuperScript™ II Reverse Transcriptase (18080044) [34]. For real-time PCR, cDNA samples were diluted 5-folds and PCR was performed with StepOne Plus Real Time PCR System (PE Applied Biosystems, CA, USA). The Fast SYBR Green Master Mix (4385612) was used for all reactions. The housekeeping gene used was RPL7 when mRNAs were analyzed and RNU6B when microRNAs were analyzed. A list of primers is shown in S1 Table.

**Immunostaining**

iPSCs lines, EBs, fibroblast cells and horse embryos were fixed in 4% paraformaldehyde for 30 minutes at room temperature, washed with PBS, and then permeabilized for 1 h in a solution containing 0.1% bovine serum albumin/PBS, 10% FBS and 0.1% Triton. After permeabilization, blocking was assessed by 1 h incubation with 3% FBS and 0.1% Tween-20 (Promega, H5152), followed by primary antibody incubation for 2 hours at room temperature. They were then washed and incubated with the secondary antibody and DAPI for 1 h at RT in the dark. Negative controls were performed using only the secondary antibody. Specific antibodies and dilutions are detailed in S2 Table.

**Somatic cell nuclear transfer**

Somatic cell nuclear transfer and embryo transfer were performed as previously described by Olivera et al [35, 36]. Briefly, equine oocytes were in vitro matured and enucleated by micro-manipulation. After oocyte enucleation, fusion of one L3 iPSC or one original fibroblast cell was applied. The reconstructed embryos were then chemically activated and in vitro cultured for one week in order to achieve the blastocyst stage. On day 2 and day 7 cleavage and blastocyst rates were assessed, respectively. Those embryos that reached the blastocyst stage were transferred to recipient mares to continue gestation until birth. Mare synchronization, embryo transfer, gestation monitoring and neonatal care was performed as previously reported by Olivera et al. [35, 36].

**In-silico microRNAs target determinations**

First we compared the sequences of 10 microRNAs in the horse and the human (miR-302a, miR-302b, miR-302c, miR-302d, miR-205, miR-145, miR-9, miR-96, miR-125b and miR-296), which were obtained in the miRBase database (www.mirbase.com) (Table 1). In order to determine whether the eca-microRNAs could target the same mRNAs as the ones reported in humans and mice, we evaluated the complementarity of the seed sequence of the miR-302 family, miR-96, miR-9 and miR-145 with the 3’UTR of possible target genes. In most reports the microRNA seed sequence is essential for the binding of the microRNA to the mRNA and it comprises a contiguous string of at least 6 nucleotides beginning at position 2 of the microRNA (the sufficient minimal set of microRNA seed type) [20]. To achieve this, the horse
The accession numbers of the genes were: eqOCT-4 (XM_001490108.6), eqKLF4 (XM_005605684.2), eqSOX2 (FJ356148.1), eqCDK2 (XM_001504790.6), eqCYCLIN D1 (XM_023654619.1), eqRHOC (XM_001917242.5), eqE2F1 (XM_023626374.1), eqHES1 (XM_001498844.5) and eqPAX6 (XM_023646562.1). Sequence alignments were performed with Geneious software and RNA22 software [37].

Transfection of episomal reprogramming vectors

Equine fibroblasts were transfected with different combinations of episomal reprogramming plasmids that have demonstrated to reprogram human cells [38–40]: pCXLE-hOCT3/4-shp53-F (addgene N˚27077), pCXLE-hSK (addgene N˚27078), pCXLE-hUL (addgene N˚27080), pEP4 E02S CK2M EN2L (addgene N˚20924) and pCXWB-EBNA1 (addgene N˚37624). Either the 100 μl tip NEON system or FuGENE6 transfection reagent (Roche, 1814443) was used for the transfection of the plasmids, following the manufacturer’s instructions in both cases. The equine fibroblasts were transfected with different conditions of plasmid concentrations, plasmid combinations and NEON settings, which are detailed in S3 Table. All the conditions were evaluated twice and the EGFP-N1 plasmid was used as control of transfection in each procedure. Once transfected, the cells were cultured in gelatin coated p100 in DMEM 10% SFB medium for 5 days. After that time, they were trypsinized and plated in different dilutions over iMEFs in eqHES medium.

Statistical analysis

Real time PCRs were analyzed with the LinReg PCR software. Statistical differences were analyzed using either paired Student’s t test or ANOVA. Comparisons between means were assessed using the Tukey test. Statistical analysis for the results of in vitro embryo development was performed using non parametric Fisher’s exact test (p<0.05).

Results

Fibroblast reprogramming and pluripotency characterization of horse iPSCs obtained by STEMCCA transduction

We attempted several times to reprogram equine fibroblasts by using different combination of episomal vectors (S3 Table). However, we could not develop equine iPSCs by this strategy.
Few reports have demonstrated the capacity to reprogram human cells with episomal vectors [38–40], nevertheless, the equine cells that were transfected with these plasmids showed changes only in shape morphology and overgrowing correlated with partial reprogramming. In contrast, after 10-12 days of viral infection with the STEMCCA lentivirus, small reprogrammed colonies appeared, resulting in horse reprogrammed cells. Several colonies were obtained, and we selected two of them based on the morphology (named L2 and L3) for full characterization (Fig 1a). The pluripotency of both iPSCs lines was assessed by different techniques. We observed high alkaline phosphatase activity in L2 and L3 lines, which has demonstrated to be an indicator of pluripotency, and we did not observe alkaline phosphatase staining in fibroblasts, as expected (Fig 1b). Moreover, high expression of pluripotency markers such as OCT-4, NANOG and REX1 was observed by end-point PCR and real time PCR using horse specific primers (Figs 1 and 2). Lower expression of these markers was observed for the fibroblast group by real time PRC and no amplification was detected by end-point PCR in this group (Figs 1 and 2). Moreover, both L2 and L3 iPSCs lines were also positive for expression of OCT-4, SOX-2 and c-MYC proteins, assessed by immunofluorescence staining, not observing any positive signal in horse fibroblasts (Fig 1c). As these three genes are also encoded by the STEMCCA virus, we ensured that the antibodies used can recognize the equine OCT-4, SOX-2 and c-MYC proteins by evaluating them in equine embryos by immunostaining shown in S1 Fig. With this control we confirmed that the antibodies can be used in the horse.

**In vitro differentiation**

We generated in vitro EBs in order to evaluate the capacity of both iPSCs lines to differentiate into the three germ layers. After colony detachment, EBs were formed in few hours in both iPSCs lines (Fig 3a). Both EB-L2 (EBs derived from L2) and EB-L3 (EBs derived from L3) showed expression of the ectodermal markers nestin, βIII-tubulin, the endodermal marker AFP and the mesodermal markers vimentin and brachyury, by end point PCR. In contrast, non-differentiated iPSCs cells were negative for these markers (Fig 2b). Immunofluorescent staining was also used to determine the protein expression of differentiated cells to the three germ layers. We assessed the expression of GATA-4, βIII-TUBULIN, VIMENTIN, SMOOTH-MUSCLE ACTIN (SMA) and NKX-2.5 by immunofluorescence in both EB-L2 and EB-L3 and observed a strong specific staining (Fig 3b). As expected, fibroblasts were negative for GATA-4, βIII-TUBULIN and NKX-2.5, but positive for vimentin and SMA, both mesodermal markers. In addition, OCT-4 and NANOG, but not REX1, were down-regulated in the EBs respect to the iPSCs lines (Fig 3c).

**Somatic cell nuclear transfer**

We compared the capacity of the horse iPSCs and fibroblasts to generate in vitro embryos and viable foals. Results using L3-iPSCs as nuclear donors are shown in Table 2. In both cases, we obtained similar cleavage rates between groups (51/56 (91.1%) and 205/246 (83.3%) for L3-iPSC and fibroblasts, respectively), but no blastocysts were generated with the pluripotent cells as nuclear donors. Those blastocysts generated with the original fibroblasts were transferred to recipient mares and 2 healthy foals were born. With these results we could determine the good quality of the embryos generated.

**microRNAs expression in horse iPSCs and differentiated EBs**

The expression of 7 different microRNAs were evaluated in fibroblasts, iPSCs lines and EBs (Figs 4 and 5). We observed that the expression of the miR-302 family (miR-302a, miR-302b,
Fig 1. Pluripotent characterization of two horse iPSC lines, L2 and L3. a) A representative colony of equine iPSCs 2 weeks after reprogramming.
b) Alkaline phosphatase activity analysis of the L2 iPSC line, I) A 60 mm petri dish full of iPSC colonies observed in pink; II) Two iPSC colonies with high alkaline phosphatase activity; III) Horse fibroblasts negative for alkaline phosphatase activity. c) Immunostaining of both iPSC lines and horse fibroblasts with the pluripotent markers OCT-4, SOX-2 and c-MYC. In blue nucleus are stained with DAPI. d) RT-qPCR analysis comparing the expression of OCT-4, NANOG and REX-1 among the original fibroblasts and the L2 and L3 iPSC lines. Results are presented as means ± SEM (n = 3). Data were relativized to fibroblasts. Different letters indicate significant differences (p<0.05).

https://doi.org/10.1371/journal.pone.0207074.g001
miR-302c and miR-302d) was strongly induced after cell reprogramming ($p < 0.05$). In addition to the miR-302, the miR-9 and the miR-96 were also up-regulated ($p < 0.05$). In all cases, no differences were observed between the two iPSCs lines. After differentiation to EBs, the miR-96 was upregulated in the EBs respect to the iPSCs, and also the expression of miR-205 was induced but only in the EB-L2 ($p < 0.05$). Finally, while miR-302 was downregulated in EBs, miR-9 was upregulated compared to iPSCs.

**microRNAs seed alignments**

We performed *in silico* analysis of some microRNAs evaluated in this paper. First, we compared the eca-miR-302/367 cluster with the hsa-miR-302/367 cluster and we determined a 75% homology between them (Fig 6a). Moreover, the seed region of the eca-miR-302 family resulted complementary to the 3'UTR of horse cell cycle regulator genes CDK2, CYCLIN D1 and E2F1, and to the 3'UTR of the RHOC gene, which is involved in the epithelial-mesenchymal transition (Fig 6a). The miR-145 seed sequence was complementary to the 3'UTR region of the Oct-4 and Klf-4 horse genes (Fig 6b). Respect to the miR-9 and miR-96, the seed sequence of these genes were complementary to HES1 and PAX-6 genes, as it was previously demonstrated in humans [27–29]. We also analyzed the target genes with the RNA22 software, confirming the complementarity evaluated by the seed sequence (S2 Fig).

**Discussion**

In this report we generated two horse iPSCs lines by using the lentiviral vector STEMCCA containing the human reprogramming factors OSKM [32]. We cultured the iPSC for more than 25 passages without losing their pluripotent characteristics and proliferation capacity. In addition to their morphology, pluripotency was assessed by the expression of OCT-4, NANOG and REX1 by end point PCR and qPCR. Similarly as in equine embryos, equine iPSCs have demonstrated to widely express these markers [8, 9, 41–43]; however, only REX1 has been associated exclusively with equine pluripotent cells [42], observing a significant expression of this gene in our iPSCs lines. Furthermore, we confirmed staining for OCT-4, SOX-2 and
Fig 3. *In vitro differentiation of L2 and L3 iPSCs to embryo bodies (EB).* a) Generation of EBs, I) EBs in suspension for 1 week in DMEM medium, II) EBs after 3 days in adherent dishes, III) EBs after 2 weeks in adherent dishes. b) Immunofluorescence of endodermal, ectodermal and mesodermal markers in EBs derived from L2 (EB-L2), L3 (EB-L3) iPSCs lines and fibroblasts as controls. In blue nucleous are stained with DAPI. c) RT-qPCR analysis of pluripotent markers in L2 vs. EB-L2 and L3 vs. EB-L3. Results are presented as means ± SEM (n = 3). Data were relativized to L2 or L3 for EB-L2 and EB-L3, respectively. *Statistically different (p<0.05).*

https://doi.org/10.1371/journal.pone.0207074.g003
C-MYC by immunocytochemistry and also high alkaline phosphatase activity. Until now, no reliable equine ESC could be isolated in this species [1, 44, 45], which makes the pluripotent characterization of the equine iPSCs more challenging [1].

In addition to the identification of these pluripotent markers, both iPSC lines could differentiate in vitro and form EBs. These EBs showed gene expression for markers of the three germ layers including NESTIN, βIII-TUBULIN, AFP, VIMENTIN and BRACHYURY, not observing expression of these genes in the original iPSCs. Moreover, we characterized the EBs by immunocytochemistry, observing positive staining for markers of the three embryonic germ layers GATA-4, βIII-TUBULIN, VIMENTIN, SMA and NKX-2.5, despite protein analysis in this model is difficult to achieve due to a lack of reliable antibodies.

We also tried to generate equine iPSCs lines with different combinations of episomal vectors that have demonstrated their potential to efficiently reprogram human cells [38–40]. We could corroborate the incorporation of the plasmids by co-transfecting a reporter vector with GFP, but we could not reprogram equine fibroblasts by this technique. Besides human cells,

### Table 2. Equine cloning using L3-iPSCs as nuclear donors.

| Groups     | Embryos | Cleavage | Blastocysts | Embryo transfers | Pregnancies | Offspring (%) |
|------------|---------|----------|-------------|------------------|-------------|---------------|
| iPSC—L3    | 56      | 51 (91.1)| 0<sup>a</sup> | -                | -           | -             |
| Fibroblasts| 246     | 205 (83.3)| 22 (8.9)<sup>b</sup> | 11               | 2 (18.2)    | 2 (100)       |

<sup>a, b</sup> Values with different superscripts in a column are significantly different (Fisher’s exact test p<0.05)

https://doi.org/10.1371/journal.pone.0207074.t002

Fig 4. RT-qPCR analysis of 7 microRNAs in the L2 and L3 iPSCs lines and the original fibroblasts. RT-qPCR analysis of 7 microRNAs in the L2 and L3 iPSCs lines and the original fibroblasts. Results are presented as means ± SEM (n = 3). Data were relativized to fibroblasts. Different letters indicate significant differences (p<0.05).

https://doi.org/10.1371/journal.pone.0207074.g004
episomal reprogramming was efficient in few species including only the mouse and the rat [12, 46], but was not efficient to generate pig iPSCs [47]. Apart from this report, no other one has been published in domestic species. The strongest hypothesis that might explain the inability to generate equine iPSCs with episomal vectors is that domestic iPSCs would require continuous expression of the transgenes to maintain pluripotency, as was previously observed [7, 48–50]. This hypothesis is also consistent with our cloning results with one of the iPSC lines. Whereas 2 viable foals were generated with the original fibroblasts, no blastocysts were obtained when the iPSCs were used as nuclear donors. The same result was previously published in the horse with a different iPSC line [35]. The continuous expression of the transgenes could be blocking specific cell determination during the first differentiation steps after morula formation.

In addition to the analysis of mRNAs we were also interested in the expression of microRNAs in horse iPSCs in order to expand our knowledge of the identity of pluripotent cells in this species. In human embryonic stem cells, specific microRNAs such as the miR-302 family are tightly connected with OCT-4, SOX-2 and NANOG mRNAs in a relative expression level that is carefully balanced in order to maintain pluripotency [51, 52]. Conversely, it was reported that miR-145 represses the expression of OCT-4, SOX-2 and KLF4 [25] and it is down-regulated in iPSCs when compared with fibroblasts [14], thus controlling reprogramming and differentiation by targeting these stem factors. In our work, we observed similar

![Fig 5. RT-qPCR analysis of 7 microRNAs in the iPSCs lines and the embryo bodies (EBs) derived from them, iPSC-L2 vs. EB-L2 and iPSC-L3 vs. EB-L3. Results are presented as means ± SEM (n = 3). EB-L2 data were relativized to iPSC-L2 data and EB-L3 data were relativized to iPSC-L3 data. *Statistically different (p<0.05).](https://doi.org/10.1371/journal.pone.0207074.g005)
results with the equine iPSCs lines. We also determined that the expression of the miR-302 family was induced in both iPSCs lines respect to the original fibroblasts. In addition, despite no differences were seen in the expression of miR-145 among the groups because of the data disparity, there is a tendency of miR-145 to be down-regulated in both horse iPSCs lines respect to the original fibroblasts, as was reported in human and pig iPSCs [53]. In consistence, the eca-miR-302/367 cluster conserves the homology and distribution in the genome similarly as in humans. Moreover, the miR-302 family seed sequence resulted complementary to eqCyclin D1 3’UTR, eqCDK2 3’UTR and eqE2F1 3’UTR, important cell cycle regulators, and eqRHO, a regulator of the mesenchymal-epithelial transition (MET).

In silico alignments determined that the eca-miR-145 seed sequence was complementary to the 3’UTR of pluripotent genes including eqKLF4 3’UTR and eqOCT-4, respectively. These determinations complemented our experimental results and let us speculate that there are similar regulations of miR-302 family and miR-145 as in humans [25, 26, 51, 54].

Other differentiation-related microRNAs as the miR-9 and miR-96 are involved in neural specification. miR-9 promotes neural lineage differentiation by inhibiting neural stem cells proliferation [55–57], and miR-96 is over-expressed in human pluripotent cells, and it is also involved in PAX6 repression, inhibiting neural induction [28, 58]. Here we observed that
miR-9 and miR-96 were also over-expressed in L2 and L3 iPSCs respect to the original fibroblasts and that miR-96 significantly enhanced its expression in the differentiated cells to EBs respect to the iPSCs. Whether this regulation is related to neural specification was not determined experimentally, but the seed sequence reported for the hsa-miR-96 [28] that is the same as the eca-miR-96 is complementary to the 3’UTR of the eqPAX6 gene. Moreover, miR-9 has demonstrated to bind the 3’UTR of the HES1 mRNA in the developing brain of the mouse, regulating the proliferation and differentiation of neural stem cells [55]. In silico alignments demonstrated that the eca-miR-9 may be able to bind the 3’-UTR of eqHes1 mRNA by its seed sequence, thus regulating the expression of this gene. With these results we consider that both miR-96 and miR-9 may also be involved in neural specification in the horse.

The other microRNAs evaluated after in vitro differentiation to EBs, did not show statistical differences respect to the iPSCs lines, but miR-302 tends to be downregulated and miR-9 tends to be upregulated in the EBs. Because the EBs have a mix of heterogenous population of cells differentiated to the three germ layers, it is possible that it could be some compensation in the quantification of the expression of the microRNAs.

**Conclusion**

In summary, we generated and characterized two horse iPSC cell lines derived from embryonic fibroblasts by lentiviral infection of the reprogramming factors, but we were not able to reprogram the same fibroblasts by using episomal vectors. Moreover, several results led us to think that the equine microRNAs evaluated in our work are highly conserved in sequence and function respect to the human species. Now, it is necessary to generate directed differentiations to derivatives of the three germ layers in order to strengthen our results. This is the first report to evaluate the expression and possible targets of microRNAs in domestic animals pluripotent cells.

**Supporting information**

**S1 Fig. Immunostaining of horse embryos at the blastocyst stage.** Positive staining for the pluripotent markers OCT-4, SOX-2 and c-MYC in equine embryos. In blue nucleous are stained with DAPI.

(TIF)

**S2 Fig. RNA22 output results.** Complementarity analysis of equine microRNAs with target transcripts.

(TIFF)

**S1 Table. List of primers used in this study.**

(DOCX)

**S2 Table. List of antibodies used in these paper.**

(DOCX)

**S3 Table. Episomal reprogramming.** Details about protocols used for cell reprogramming using episomal vectors.

(DOCX)

**Author Contributions**

**Conceptualization:** Santiago Gabriel Miriuka.

**Data curation:** Guadalupe Amin, Ariel Waisman, Alejandro La Greca.
Formal analysis: Guadalupe Amin, Ariel Waisman, Ximena Garate, Gabriel Neiman, Alejandro La Greca, Natalia Lucia Santí ´ n Velazque.

Investigation: Lucia Natalia Moro, Veronica Furmento, Gabriel Neiman, Carlos Luzzani, Gabriel Vichera, Santiago Gabriel Miriuka.

Methodology: Lucia Natalia Moro, Guadalupe Amin, Veronica Furmento, Ximena Garate, Natalia Lucia Santí ´ n Velazque, Gabriel Vichera.

Resources: Gustavo E. Sevlever.

Supervision: Santiago Gabriel Miriuka.

Writing – original draft: Lucia Natalia Moro.

Writing – review & editing: Veronica Furmento, Ariel Waisman, Gabriel Neiman, Alejandro La Greca, Carlos Luzzani, Gustavo E. Sevlever, Gabriel Vichera, Santiago Gabriel Miriuka.

References
1. Blomberg LA, Telugu BPVL. Twenty years of embryonic stem cell research in farm animals. Reprod Domest Anim. 2012; 47 Suppl 4:80–5. https://doi.org/10.1111/j.1439-0531.2012.02059.x PMID: 22827354
2. Smith RKW, Werling NJ, Dakin SG, Alam R, Goodship AE, Duchia J. Beneficial effects of autologous bone marrow-derived mesenchymal stem cells in naturally occurring tendinopathy. PLoS One. 2013; 8(9):e75697. https://doi.org/10.1371/journal.pone.0075697 PMID: 24086616
3. Broeckx S, Zimmerman M, Crocetti S, Suls M, Mariën T, Ferguson SJ, et al. Regenerative therapies for equine degenerative joint disease: a preliminary study. PLoS One. 2014; 9(1):e89917. https://doi.org/10.1371/journal.pone.0089917 PMID: 2465787
4. Geburek F, Roggel F, van Schie HTM, Beineke A, Estrada R, Weber K, et al. Effect of single intrale-sional treatment of surgically induced equine superficial digital flexor tendon core lesions with adipose-derived mesenchymal stromal cells: a controlled experimental trial. Stem Cell Res Ther. 2017; 8(1):129. https://doi.org/10.1186/s13287-016-0564-8 PMID: 28583184
5. Egusa H, Kayashima H, Miura J, Uraguchi S, Wang F, Okawa H, et al. Comparative analysis of mouse-induced pluripotent stem cells and mesenchymal stem cells during osteogenic differentiation in vitro. Stem Cells Dev. 2014; 23(18):2156–69. https://doi.org/10.1089/scd.2013.0344 PMID: 24625139
6. Lee EM, Kim AY, Lee EJ, Park JK, Park SI, Cho SG, et al. Generation of Equine-Induced Pluripotent Stem Cells and Analysis of Their Therapeutic Potential for Muscle Injury. Cell Transplant. 2016; 25(11):2003–2016. https://doi.org/10.1277/j006368916X691691 PMID: 2726077
7. Nagy K, Sung HK, Zhang P, Laffamme S, Vincent P, Agha-Mohammadi S, et al. Induced pluripotent stem cell lines derived from equine fibroblasts. Stem Cell Rev. 2011; 7(3):693–702. https://doi.org/10.1007/s12015-011-9239-5 PMID: 21347602
8. Khodadadi K, Sumer H, Parsaial A, Mil S, Williams M, Verma PJ. Induction of pluripotency in adult equine fibroblasts without c-MYC. Stem Cells Int. 2012; 2012:429160. https://doi.org/10.1155/2012/429160 PMID: 22550508
9. Breton A, Sharma R, Diaz AC, Parham AG, Graham A, Neil C, et al. Derivation and characterization of induced pluripotent stem cells from equine fibroblasts. Stem Cells Dev. 2013; 22(4):611–21. https://doi. org/10.1089/scd.2012.0052 PMID: 22897112
10. Greve TS, Judson RL, Bleiloch R. microRNA control of mouse and human pluripotent stem cell behavior. Annu Rev Cell Dev Biol. 2013; 29:213–239. https://doi.org/10.1146/annurev-cellbio-101512-122343 PMID: 23875649
11. Yang CS, Rana TM. Learning the molecular mechanisms of the reprogramming factors: let’s start from microRNAs. Mol Biosyst. 2013; 9(1):10–7. https://doi.org/10.1039/c2mb25088h PMID: 23035750
12. Li N, Long B, Han W, Yuan S, Wang K. microRNAs: important regulators of stem cells. Stem Cell Res Ther. 2017; 8(1):110. https://doi.org/10.1186/s13287-017-0551-0 PMID: 28494789
13. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol. 2011; 13(11):1353–60. https://doi.org/10.1038/ncb2366 PMID: 22020437
14. Barta T, Peskova L, Collin J, Montaner D, Neganova I, Armstrong L, et al. Brief Report: Inhibition of miR-145 Enhances Reprogramming of Human Dermal Fibroblasts to Induced Pluripotent Stem Cells. Stem Cells. 2016; 34(1):246–51. https://doi.org/10.1002/stem.2220 PMID: 26418476

15. Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miR-NAs. Curr Opin Struct Biol. 2005; 15(3):331–41. https://doi.org/10.1016/j.sbi.2005.05.006 PMID: 15925505

16. Aravin A, Tuschl T. Identification and characterization of small RNAs involved in RNA silencing. FEBS Lett. 2005; 579(26):5830–40. https://doi.org/10.1016/j.febslet.2005.08.009 PMID: 16153643

17. Xu W, San Lucas A, Wang Z, Liu Y. Identifying microRNA targets in different gene regions. Cell Stem Cell. 2011; 8(4):376–88. https://doi.org/10.1016/j.stem.2011.03.001 PMID: 21474102

18. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell. 2011; 8(6):2858–63. https://doi.org/10.1016/j.stem.2011.05.001 PMID: 21386720

19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215–33. https://doi.org/10.1016/j.cell.2009.01.002 PMID: 19167326

20. Ellwanger DC, Büttner FA, Mewes HW, Stumpflen V. The sufficient minimal set of miRNA seed types. Bioinformatics. 2011; 27(10):1346–50. https://doi.org/10.1093/bioinformatics/btr149 PMID: 21441577

21. Alwin Prem Anand A, Huber C, Asnet Mary J, Gallus N, Leucht C, Klafke R, et al. Expression and function of microRNA-9 in the mid-hindbrain area of embryonic chick. BMC Dev Biol. 2018; 23(2). https://doi.org/10.1371/journal.pone.0207074

22. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KL4 and represses pluripotency in human embryonic stem cells. Cell. 2009; 137(4):647–58. https://doi.org/10.1016/j.cell.2009.02.038 PMID: 19409607

23. Du ZW, Ma LX, Phillips C, Zhang SC. miR-200 and miR96 families repress neural induction from human embryonic stem cells. Development. 2013; 140(12):2611–8. https://doi.org/10.1242/dev.092809 PMID: 23637338

24. Judson RL, Babiarz JE, Venere M, Bielloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol. 2009; 27(5):459–61. PMID: 19363475

25. Sommer CA, Stadtfeld M, Murphy GJ, Hochedlinger K, Kotton DN, Mostoslavsky G. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells. 2009; 27(3):543–9. https://doi.org/10.1634/stemcells.2008-1075 PMID: 19096035

26. Questa M, Romorini L, Blügguermann C, Solar CM, Neigen G, Luzzani C, et al. Generation of iPSC line iPSC-FH2.1 in hypoxic conditions from human foreskin fibroblasts. Stem Cell Res. 2016; 16(2):300–3. https://doi.org/10.1016/j.scr.2015.12.026 PMID: 27345989
34. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of micro-RNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005; 33(20):e179. https://doi.org/10.1093/nar/gni178 PMID: 16314309

35. Olivera R, Moro LN, Jordan R, Luzzani C, Miriuka S, Radrizzani M, et al. In Vitro and In Vivo Development of Horse Cloned Embryos Generated with iPSCs, Mesenchymal Stromal Cells and Fetal or Adult Fibroblasts as Nuclear Donors. PLoS One. 2016; 11(10):e0164049. https://doi.org/10.1371/journal.pone.0164049 PMID: 27732616

36. Olivera R, Moro LN, Jordan R, Pallarols N, Guglielminetti A, Luzzani C, et al. Bone marrow mesenchymal stem cells as nuclear donors improve viability and health of cloned horses. Stem Cells Cloning. 2018; 11:13–22. https://doi.org/10.2147/SCCAA.S151763 PMID: 29497320

37. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006; 126(6):1203–17. https://doi.org/10.1016/j.cell.2006.07.031 PMID: 16990141

38. Yu J, Hu K, Smuga-Otto K, Tian R, Slukvin II, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009; 324(5928):797–801. https://doi.org/10.1126/science.1172482 PMID: 19325077

39. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPSCs. Nat Methods. 2011; 8(5):409–12. https://doi.org/10.1038/nmeth.1591 PMID: 21460823

40. Drozd AM, Walczak MP, Piaskowski S, Stoczynska-Fidelus E, Rieske P, Grzela DP. Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system. Stem Cell Res Ther. 2018; 11:13–22. https://doi.org/10.1186/s13287-015-0112-3 PMID: 26088261

41. Guest DJ, Allen WR. Expression of cell-surface antigens and embryonic stem cell pluripotency genes in equine blastocysts. Stem Cells Dev. 2007; 16(5):789–96. https://doi.org/10.1089/scd.2007.0032 PMID: 17999600

42. Esteves CL, Sharma R, Dawson L, Taylor SE, Pearson G, Keen JA, et al. Expression of putative markers of pluripotency in equine embryonic and adult tissues. Vet J. 2014; 202(3):533–5. https://doi.org/10.1016/j.tjvl.2014.08.026 PMID: 25241949

43. Whitworth DJ, Ovchinnikov DA, Sun J, Fortuna PRJ, Wolverton EJ. Generation and characterization of leukemia inhibitory factor-dependent equine induced pluripotent stem cells from adult dermal fibroblasts. Stem Cells Dev. 2014; 23(13):1515–23. https://doi.org/10.1089/scd.2013.0461 PMID: 24555755

44. Saito S, Ugai H, Sawai K, Yamamoto Y, Minamihashi A, Kurosaka K, et al. Isolation of embryonic stem-like cells from equine blastocysts and their differentiation in vitro. FEBS Lett. 2002; 531(3):389–96. https://doi.org/10.1016/S0014-5793(02)03550-0 PMID: 12435581

45. Li X, Zhou SG, Imreh MP, Ahlstrand-Richter L, Allen WR. Horse embryonic stem cell lines from the proliferation of inner cell mass cells. Stem Cells Dev. 2006; 15(4):523–51. https://doi.org/10.1089/scd.2006.15.523 PMID: 16978056

46. Wu S, Wu Y, Zhang X, Capecci MR. Efficient germ-line transmission obtained with transgene-free induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2014; 111(23):8078–83. https://doi.org/10.1073/pnas.1400666111 PMID: 25020522

47. Du X, Feng T, Yu D, Wu Y, Zou H, Ma S, et al. Barriers for Deriving Transgene-Free Pig iPS Cells with Episomal Vectors. Stem Cells. 2015; 33(11):3228–38. https://doi.org/10.1002/stem.2089 PMID: 26138940

48. Esteban MA, Xu J, Yang J, Peng M, Qin D, Li W, et al. Generation of induced pluripotent stem cell lines from Tibetan miniature pig. J Biol Chem. 2009; 284(26):17634–40. https://doi.org/10.1074/jbc.M109.008938 PMID: 19376775

49. Ezashi T, Telugu BPVL, Alexenko AP, Sachdev S, Sinha S, Roberts RM. Derivation of induced pluripotent stem cells from pig somatic cells. Proc Natl Acad Sci U S A. 2009; 106(27):10993–8. https://doi.org/10.1073/pnas.0905284106 PMID: 19541600

50. Sumer H, Liu J, Malaver-Ortega LF, Lim ML, Khodadadi K, Verma PJ. NANOG is a key factor for induction of pluripotency in bovine adult fibroblasts. J Anim Sci. 2011; 89(9):2708–16. https://doi.org/10.2527/jas.2010-3666 PMID: 21478453

51. Card DAG, Hebbard PB, Li L, Trotter KW, Komatsu Y, Mishina Y, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol. 2008; 28(20):6426–38. https://doi.org/10.1128/MCB.00359-08 PMID: 18710938

52. Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell. 2008; 134(3):521–33. https://doi.org/10.1016/j.cell.2008.07.020 PMID: 18692474
53. Zhang W, Zhong L, Wang J, Han J. Distinct MicroRNA Expression Signatures of Porcine Induced Pluripotent Stem Cells under Mouse and Human ESC Culture Conditions. PLoS One. 2016; 11(7): e0158655. https://doi.org/10.1371/journal.pone.0158655 PMID: 27384321

54. Subramaniam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol. 2011; 29(5):443–8. https://doi.org/10.1038/nbt.1862 PMID: 21490602

55. Tan SL, Ohtsuka T, González A, Kageyama R. MicroRNA9 regulates neural stem cell differentiation by controlling Hes1 expression dynamics in the developing brain. Genes Cells. 2012; 17(12):952–61. https://doi.org/10.1111/gtc.12009 PMID: 23134481

56. Krichevsky AM, Sonntag KC, Isacson O, Kosik KS. Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells. 2006; 24(4):857–64. https://doi.org/10.1634/stemcells.2005-0441 PMID: 16357340

57. Zhao C, Sun G, Li S, Shi Y. A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. Nat Struct Mol Biol. 2009; 16(4):365–71. https://doi.org/10.1038/nsmb.1576 PMID: 19330006

58. Zhang X, Huang CT, Chen J, Pankratz MT, Xi J, Li J, et al. Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell. 2010; 7(1):90–100. https://doi.org/10.1016/j.stem.2010.04.017 PMID: 20621053